← Leaderboards
Luc Teyton
Scripps Research Institute, The
$46,887,049
Attributed
$47,964,685
Total exposure
29
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,895,069 · 30
By mechanism
R01$29,987,017 · 10
P01$11,536,173 · 10
U01$7,236,382 · 2
R21$1,258,436 · 2
UG3$1,232,846 · 1
TL1$1,157,779 · 1
Top collaborators
- Katja A Lamia2 shared
- Christopher C. W. Hughes1 shared
- Jeffrey Robert Millman1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsAntigensT-LymphocyteB-LymphocytesIn VivoProgramsProteinsMolecularAntibodiesComplexImmune ResponseResponseImmuneSuccessDesignStructureSeriesBaseAnimalsAffinityGrantIn VitroPeptidesLink
Grant awards (97)
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections$1,961,391
P01 · FY2025 · AI · contact PI
Studying the mechanisms of initiation and progression of Beta cell death in T1D$1,232,846
UG3 · FY2025 · DK · contact PI
Initiation of anti-islet autoimmunity: Regulation of MHC class II expression in the islet microenvironment$801,662
R01 · FY2025 · DK · contact PI
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines$694,960
U01 · FY2025 · AI · contact PI
Molecular basis of glycan recognition by T and B cells$471,585
P01 · FY2025 · AI · contact PI
CTSA Postdoctoral T32 at The Scripps Research Institute$254,761
T32 · FY2025 · TR
Antibody Core$194,587
P01 · FY2025 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$152,864
R56 · FY2025 · DK · contact PI
Administrative Core$38,721
P01 · FY2025 · AI · contact PI
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections$1,943,996
P01 · FY2024 · AI · contact PI
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D$740,696
R01 · FY2024 · DK · contact PI
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines$687,160
U01 · FY2024 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$500,382
R56 · FY2024 · DK · contact PI
Molecular basis of glycan recognition by T and B cells$454,191
P01 · FY2024 · AI · contact PI
CTSA Postdoctoral T32 at The Scripps Research Institute$256,717
T32 · FY2024 · TR
Antibody Core$194,588
P01 · FY2024 · AI · contact PI
Administrative Core$38,721
P01 · FY2024 · AI · contact PI
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections$2,024,997
P01 · FY2023 · AI · contact PI
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D$762,477
R01 · FY2023 · DK · contact PI
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines$678,060
U01 · FY2023 · AI · contact PI
Molecular basis of glycan recognition by T and B cells$454,191
P01 · FY2023 · AI · contact PI
Antibody Core$194,588
P01 · FY2023 · AI · contact PI
Administrative Core$38,721
P01 · FY2023 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$788,462
R01 · FY2022 · DK · contact PI
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines$678,060
U01 · FY2022 · AI · contact PI
NRSA Training Core$241,993
TL1 · FY2022 · TR · contact PI
Development of the Next Generation of Conjugate Vaccines$843,503
R01 · FY2021 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$788,774
R01 · FY2021 · DK · contact PI
Biology of α-linked glycosylceramides in the immune system$723,259
R01 · FY2021 · AI · contact PI
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines$699,766
U01 · FY2021 · AI · contact PI
NRSA Training Core$222,353
TL1 · FY2021 · TR · contact PI
Development of the Next Generation of Conjugate Vaccines$844,945
R01 · FY2020 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$789,010
R01 · FY2020 · DK · contact PI
Biology of α-linked glycosylceramides in the immune system$723,259
R01 · FY2020 · AI · contact PI
NRSA Training Core$219,010
TL1 · FY2020 · TR · contact PI
Increasing the Social Science Impact of Biomedical Research$34,123
TL1 · FY2020 · TR · contact PI
Development of the Next Generation of Conjugate Vaccines$846,375
R01 · FY2019 · AI · contact PI
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis$812,694
R01 · FY2019 · DK · contact PI
Biology of α-linked glycosylceramides in the immune system$723,259
R01 · FY2019 · AI · contact PI
Role of Lymphangiogenesis in the Initiation and Progression of Type 1 Diabetes$241,875
R21 · FY2019 · AI · contact PI
NRSA Training Core$215,744
TL1 · FY2019 · TR · contact PI
Development of the Next Generation of Conjugate Vaccines$894,543
R01 · FY2018 · AI · contact PI
Biology of α-linked glycosylceramides in the immune system$723,259
R01 · FY2018 · AI · contact PI
Role of Lymphangiogenesis in the Initiation and Progression of Type 1 Diabetes$290,250
R21 · FY2018 · AI · contact PI
NRSA Training Core$224,556
TL1 · FY2018 · TR · contact PI
Biology of α-linked glycosylceramides in the immune system$746,384
R01 · FY2017 · AI · contact PI
Molecular Pharmacology of NKT Cell Agonists$727,292
R01 · FY2017 · AI · contact PI
Production of high affinity anti-glycan and anti-glycolipid antibodies$352,304
R21 · FY2017 · AI · contact PI
Molecular Pharmacology of NKT Cell Agonists$727,292
R01 · FY2016 · AI · contact PI
Production of high affinity anti-glycan and anti-glycolipid antibodies$374,007
R21 · FY2016 · AI · contact PI
Molecular Pharmacology of NKT Cell Agonists$717,836
R01 · FY2015 · AI · contact PI
Molecular Mechanisms Linking HLA-DQ and Autoimmunity$558,665
R01 · FY2015 · AI · contact PI
Molecular Pharmacology of NKT Cell Agonists$717,836
R01 · FY2014 · AI · contact PI
Molecular Mechanisms Linking HLA-DQ and Autoimmunity$558,665
R01 · FY2014 · AI · contact PI
Molecular Pharmacology of NKT Cell Agonists$697,142
R01 · FY2013 · AI · contact PI
Molecular Mechanisms Linking HLA-DQ and Autoimmunity$525,146
R01 · FY2013 · AI · contact PI
HT screens for the disruption of the T cell receptor CD3 interface$520,179
R01 · FY2013 · AI · contact PI
BioMark$321,712
S10 · FY2013 · OD · contact PI
Immune Recognition of Glycolipids$630,105
P01 · FY2012 · AI · contact PI
Molecular Mechanisms Linking HLA-DQ and Autoimmunity$558,665
R01 · FY2012 · AI · contact PI
HT screens for the disruption of the T cell receptor CD3 interface$555,275
R01 · FY2012 · AI · contact PI
Production of Recombinant CD1d Molecules$81,466
P01 · FY2012 · AI · contact PI
Molecular Mechanisms Linking HLA-DQ and Autoimmunity$652,951
R01 · FY2011 · AI · contact PI
HT screens for the disruption of the T cell receptor CD3 interface$568,500
R01 · FY2011 · AI · contact PI
Immune Recognition of Glycolipids$544,089
P01 · FY2011 · AI · contact PI
Production of Recombinant CD1d Molecules$114,720
P01 · FY2011 · AI · contact PI
Using Lipids for Vaccination$773,720
U01 · FY2010 · AI · contact PI
Immune Recognition of Glycolipids$550,804
P01 · FY2010 · AI · contact PI
Production of Recombinant CD1d Molecules$115,906
P01 · FY2010 · AI · contact PI
Using Lipids for Vaccination$758,772
U01 · FY2009 · AI · contact PI
Immune Recognition of Glycolipids$541,514
P01 · FY2009 · AI · contact PI
Production of Recombinant CD1d Molecules$113,817
P01 · FY2009 · AI · contact PI
Using Lipids for Vaccination$48,121
U01 · FY2009 · AI · contact PI
Using Lipids for Vaccination$736,674
U01 · FY2008 · AI · contact PI
Immune Recognition of Glycolipids$531,090
P01 · FY2008 · AI · contact PI
Structural Basis of Murine Diabetes$530,024
R01 · FY2008 · DK · contact PI
Production of Recombinant CD1d Molecules$115,852
P01 · FY2008 · AI · contact PI
Molecular Immunology of MHC-Restricted T Cell Responses$781,230
R01 · FY2007 · AI · contact PI
Using Lipids for Vaccination$715,234
U01 · FY2007 · AI · contact PI
Structural Basis of Murine Diabetes$525,089
R01 · FY2007 · DK · contact PI
Molecular Immunology of MHC-Restricted T Cell Responses$781,130
R01 · FY2006 · AI · contact PI
Using Lipids for Vaccination$765,855
U01 · FY2006 · AI · contact PI
Structural Basis of Murine Diabetes$525,019
R01 · FY2006 · DK · contact PI
3D structure of LPS binding proteins and CD14$186,533
P01 · FY2006 · GM · contact PI
Molecular Immunology of MHC-Restricted T Cell Responses$776,629
R01 · FY2005 · AI
Structural Basis of Murine Diabetes$521,994
R01 · FY2005 · DK
Molecular Immunology of MHC-Restricted T Cell Responses$754,008
R01 · FY2004 · AI
Structural Basis of Murine Diabetes$506,790
R01 · FY2004 · DK
Molecular Immunology of MHC-Restricted T Cell Responses$667,245
R01 · FY2003 · AI
STRUCTURAL BASIS OF MURINE DIABETES$447,893
R01 · FY2003 · DK
IMMUNOLOGY OF MHC CLASS I-RESTRICTED T CELL RESPONSES$447,930
R01 · FY2002 · AI
STRUCTURAL BASIS OF MURINE DIABETES$434,850
R01 · FY2002 · DK
Core--Biological Reagents$0
U54 · FY2002 · AI
IMMUNOLOGY OF MHC CLASS I-RESTRICTED T CELL RESPONSES$434,884
R01 · FY2001 · AI
STRUCTURAL BASIS OF MURINE DIABETES$401,893
R01 · FY2001 · DK
IMMUNOLOGY OF MHC CLASS I-RESTRICTED T CELL RESPONSES$422,217
R01 · FY2000 · AI
STRUCTURAL BASIS OF MURINE DIABETES$390,187
R01 · FY2000 · DK